Ad
related to: expected findings for hemophilia- Patient Resources
Find helpful resources and videos
for rare bleeding disorders.
- Active Lifestyle Benefits
Why moving more is a good move.
Bleeding disorders and exercise.
- Education Specialists
Find a disease education
specialist near you.
- Blood Clots & Coagulation
A quick look at bleeding disorders.
Learn about the basics.
- Patient Resources
Search results
Results from the WOW.Com Content Network
Haemophilia (British English), or hemophilia (American English) [6] (from Ancient Greek αἷμα (haîma) 'blood' and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
The diagnosis of haemophilia A may be suspected as coagulation testing reveals an increased partial thromboplastin time (PTT) in the context of a normal prothrombin time (PT) and bleeding time. PTT tests are the first blood test done when haemophilia is indicated. [12] However, the diagnosis is made in the presence of very low levels of factor ...
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
Haemophilia B, also spelled hemophilia B, is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency (haemophilia A). [3]
Between 2024 and 2034, hemophilia treatment is predicted to register a CAGR of 4.4%. Worldwide, the hemophilia treatment market is expected to reach USD 18.7 billion by 2034. The disease hemophilia is characterized by a loss of clotting proteins in the blood, resulting in life-threatening bleeding.
Contaminated hemophilia blood products were a serious public health problem in the late 1970s up to 1985. Hemophilia A causes a deficiency in Factor VIII , a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [ 1 ]
Haemophilus influenzae (formerly called Pfeiffer's bacillus or Bacillus influenzae) is a Gram-negative, non-motile, coccobacillary, facultatively anaerobic, capnophilic pathogenic bacterium of the family Pasteurellaceae.
If a coagulation factor is part of the contact activation or tissue factor pathway, a deficiency of that factor will affect only one of the tests: Thus hemophilia A, a deficiency of factor VIII, which is part of the contact activation pathway, results in an abnormally prolonged aPTT test but a normal PT test. Deficiencies of common pathway ...
Ad
related to: expected findings for hemophilia